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Background
Malaria is one of the most significant causes of morbidity
and mortality worldwide, causing approximately 881,000
deaths every year [1]. The current WHO guidelines for the
treatment of malaria recommend the use of artemisinin-
based combination therapy (ACT) owing to the rising
threat of Plasmodium falciparum resistance to mono-
therapy [2]. Artemether/lumefantrine (AL) was the first
fixed-dose combination of ACT to be approved by the
European regulatory authorities according to the require-
ments of the International Committee on Harmonization
(ICH). AL is also pre-qualified by WHO for efficacy, safety
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Abstract
This article reviews the comprehensive data on the safety and tolerability from over 6,300 patients
who have taken artemether/lumefantrine (Coartem®) as part of Novartis-sponsored or
independently-sponsored clinical trials.The majority of the reported adverse events seen in these
studies are mild or moderate in severity and tend to affect the gastrointestinal or nervous systems.
These adverse events,which are common in both adults and children,are also typical of symptoms
of malaria or concomitant infections present in these patients. The wealth of safety data on
artemether/lumefantrine has not identified any neurological, cardiac or haematological safety
concerns. In addition, repeated administration is not associated with an increased risk of adverse
drug reactions including neurological adverse events.This finding is especially relevant for children
from regions with high malaria transmission rates who often receive many courses of anti-malarial
medications during their lifetime. Data are also available to show that there were no clinically
relevant differences in pregnancy outcomes in women exposed to artemether/lumefantrine com-
pared with sulphadoxine-pyrimethamine during pregnancy.The six-dose regimen of artemether/
lumefantrine is therefore well tolerated in a wide range of patient populations. In addition, post-
marketing experience, based on the delivery of 250 million treatments as of July 2009, has not
identified any new safety concerns for artemether/lumefantrine apart from hypersensitivity and
allergies, known class effects of artemisinin derivatives.
Open Accessand quality and is marketed as Coartem® for use as a six-
dose regimen in infants, children and adults with acute,
uncomplicated infection due to P. falciparum or mixed
infections including P. falciparum [3,4].
The efficacy of AL has been confirmed in many different
patient populations around the world and is discussed
elsewhere in this supplement [5]. This article reviews the
comprehensive safety data on AL that has been reported
in the scientific literature from Novartis-sponsored and
independent clinical trials.
Novartis-sponsored studies
Six Novartis-sponsored clinical studies [6–11] have been
conducted to assess efficacy and safety of the six-dose
regimen of AL, with safety data from these summarized in
Table 1. These studies were conducted in different regions
of the world and so included patients who lived in areas
with varying levels of drug resistant P. falciparum and
malaria endemicity. Some of the studies included other
anti-malarial drugs as active comparators [7,8], one
allowed the inclusion of patients with mixed infections
that included P. falciparum [10], and one utilized a disper-
sible paediatric formulation [11].
In all of these studies AL was well tolerated and most
reported adverse events were of mild or moderate severity.
Reported adverse events occurred mainly in the nervous
system or gastrointestinal system and were considered
typical of the symptomatology of malaria or concomitant
infections. No cardiac, neurological or audiological safety
issues were identified in the studies that assessed these
safety parameters [6–11].
Comparative results from independent studies
Many independent trials on AL have also been published
in the scientific literature. Results from the studies
conducted in Africa [12–32] are summarized in Table 2
and the results from studies conducted in Asia [33–39] in
Table 3. The safety findings from these trials confirm the
results of the Novartis-sponsored studies, namely that the
majority of adverse events were mild or moderate in
severity, tended to affect the gastrointestinal or nervous
system, and were consistent with the symptoms of
malaria. Serious adverse events were infrequent and were
unrelated or unlikely to be related to study medication.
Data have also been pooled to provide a more complete
assessment of the safety and tolerability of AL in a large
number (>1,900) of adult and paediatric patients. The
results of two of these meta-analyses, Mueller et al and
Makanga et al are shown in Table 4 [40,41]. These pooled
results confirm earlier data and show that AL is generally
well tolerated with the majority of reported adverse events
again affecting either the gastrointestinal or nervous
systems and of mild or moderate severity [40,41]. Few
adverse events were considered by the investigators to be
drug-related – most were regarded as being related to the
symptomatology of malaria. Serious adverse events
occurred infrequently [40,41]. There were, however, some
differences in the adverse event profile in children when
different body weights were compared, but this is unlikely
to be of clinical relevance. Instead, it is more likely to be
related to the subjective nature of these adverse events
and the differences in the ability of young infants and
children to verbalize these complaints [41].
Special safety considerations
Neurological and audiological safety
There have been case reports of neurological problems
(including ataxia, nystagmus, tremor and slurred speech)
occurring after administration of herbal artemisinin [42]
or artesunate monotherapy [43,44]. However, it is ques-
tionable whether these neurological effects are related to
artemisinin treatment [45–47]. Indeed, this is not suppor-
ted by audiology case-control [48–50] or other audiology
data [14,51], although additional analyses are often called
for to investigate this fully. There were, however, no
neurological or audiological safety concerns identified for
AL in the Novartis-sponsored studies [6–10,52] as shown
in Table 1. In addition, audiological data are currently
being analysed from a Novartis-sponsored study in 265
patients treated with AL, malarone or mefloquine-artesu-
nate. [Personal communication with Novartis, study
A2417). A routine review of the data collected from the first
85 patients, however, did not raise any safety concerns.
Neurological or audiological safety concerns have not
been identified in the African studies by Bukirwa et al
[12], Gürkov et al [14], and Adjei et al [20], as shown in
Table 2, Asian studies by Krudsood et al [33], and Mayxay
et al [35], as shown in Table 3, and in the pooled analyses
reported by Mueller et al [40] or Makanga et al [41], which
are summarized in Table 4.
Cardiac safety
Lumefantrine is chemically related to halofantrine, an
anti-malarial known to be associated with significant
prolongation of QTc interval. Indeed, QTc prolongation is
a known class effect of many anti-malarial drugs. As such,
cardiac safety has been thoroughly investigated during the
preclinical and clinical development of AL.
The effects of lumefantrine and its major metabolite
desbutyl-lumefantrine on wild-type hERG K+ channels
have been investigated in stably transfected human
embryonic kidney cells (HEK293) using a whole cell
patch-clamp technique [52]. This in vitro hERG channel
assay showed that lumefantrine and desbutyl-lumefan-
trine have higher IC50 values (approximately 200-fold)
than halofantrine (see Table 5). In addition, the calculated
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Table 1 – Key clinical studies evaluating the safety of the six-dose regimen of AL.
Number given 
Study AL  compared  Participating 
number Design Comparator  Patients with total  countries  Key safety findings 
van Vugt  Randomized, Six-dose  Adults &  120 out  Thailand Possible treatment-related AEs were reported 
et al 1999  double-blind regimen  children  of 359† by 16.7% of patients.These AEs could also have 
[6] (>2 years) been related to malaria and were mild or 
moderate in severity. No neurological or cardiac 
safety issues were identified.
van Vugt  Randomized, MAS* Adults &  150 out  Thailand Most AEs considered drug-related were mild or 
et al 2000  open-label children  of 200 moderate in severity. Possibly related AEs 
[7] (≥2 years) occurred at a frequency of 22% in the AL group 
compared with 46% in the MAS group. In the AL 
group 6% had nervous system AEs compared 
with 34% in the MAS group (relative risk: 0.18;
p<0.0001). Gastrointestinal AEs were also less 
frequent in the AL compared with MAS groups 
(12.7% vs 26%; relative risk: 0.49; p<0.043). No 
ECG abnormalities were identified.
Lefèvre Randomized, MAS* Adults &  164 out  Thailand Nearly 90% in both treatment groups reported 
et al 2001  open-label adolescents  of 219 treatment emergent signs/symptoms and these 
[8] (≥12 years) were of mild or moderate severity. 18.3% of 
patients taking AL and 21.8% of patients taking 
MAS reported gastrointestinal symptoms while 
27.4% and 16.4% of patients, respectively 
reported headache, dizziness and sleep disorder.
Skin reactions were reported by 4.9% of 
patients taking AL and 3.6% of patients taking 
MAS.There were no cardiac complications and 
no significant renal, hepatic or haemopoietic 
dysfunction.
Falade  Open-label Nil Infants &  310 Kenya, The most commonly reported AEs were cough,
et al 2005  children  Tanzania, anaemia, anorexia, vomiting and diarrhoea. Some 
[9] (5 to 25 kg) Nigeria differences in AEs were seen in the different 
body weight groups but as these were generally 
mild, differences were not considered clinically 
relevant. Only one patient had a SAE (urticaria) 
that was considered to be related to study 
medication and this event resolved when 
treatment was withdrawn. No cardiac safety 
issues were identified and there were no 
significant abnormal laboratory values associated 
with AL treatment.
Hatz  Open-label  Nil Adult, non- 165 EU, Treatment was well tolerated and most AEs 
et al 2008  immune  Colombia were mild or moderate in severity.The most 
[10] travellers  frequently reported AEs were headache,
insomnia, diarrhoea, nausea and vomiting and 
these AEs (along with anorexia, vertigo and 
chills) were most probably related to signs and 
symptoms of malaria. No allergic reactions were 
reported in any of the patients.There were few 
SAEs and none of these were considered related 
to AL. No significant effects were observed 
during ECGs and there were no significant 
effects seen with regard to laboratory 
parameters.
Continued overleafcardiac safety indices, which are over 30 for lumefantrine,
suggest that lumefantrine and its major metabolite pose
an unlikely risk of cardiotoxocity compared with
halofantrine [52]. A phase I, parallel group study with AL,
moxifloxacin and placebo arms (n=42 per group) was
conducted in healthy volunteers to assess cardiac safety
[52]. As shown in Figure 1, this study demonstrated that
the six-dose regimen of AL was associated with a mean
maximum increase in QTc (Fridericia’s formula) of 7.45
msec compared with placebo (90% CI: 4.4 to 10.5 msec)
in healthy volunteers. By comparison, the effect on QTc
(Fridericia’s formula) was much greater after dosing with
moxifloxacin, the positive control. A formal analysis of
the relationship between the plasma concentration of
lumefantrine and the change from mean baseline in QTc
(Fridericia’s formula) was conducted (see Figure 2). This
shows that the 95% confidence limit for the mean
lumefantrine plasma concentration does not cross the
upper confidence band for the threshold of relevance for
change in QTc (Fridericia’s formula).
One possible explanation for the alterations in QTc seen
with AL may be due to malaria itself and recovery from
this disease, as well as to stress and anaemia. These
conditions can affect cardiac electrophysiology and may
lengthen the QT interval [53]. As QT correction formulae
are based on a normal heart rate of 60 beats/minute, and
patients with malaria tend to have elevated heart rates
that decrease with successful treatment and defervescence,
overcorrection of the QT interval can also occur. This is
even more pronounced in small children, and heart rates
higher than 60 beats/minute are routinely seen in healthy
children. Despite the changes in QTc associated with
malaria, no adverse events attributable to QTc prolon-
gation (e.g. syncope or sudden death) have been reported
in clinical trials with AL [6] as shown in Table 1 [6–11],
Table 3 [39], and Table 4 [40,41].
Haematological safety
Preclinical data suggested that repeated exposure to AL
may affect blood cell counts and as such, particular
attention was paid to haemoglobin levels and haemato-
logical adverse events reported during clinical trials. A
published pooled analysis of 15 trials conducted in China,
India, Thailand, The Gambia, Tanzania, France, The
Netherlands and the UK confirmed these results [54].
Indeed, in this analysis, anaemia and thrombocytopaenia
were frequently present at baseline, but returned to normal
or improved considerably with the resolution of disease
[54]. No haematological safety concerns were identified
during the safety assessment presented in this review.
Safety of repeated administration
Most safety data on antimalarials are collected as part of
clinical trials and these tend to evaluate the treatment of
a single episode of malaria. In practice, however, children
in areas of high malaria endemicity are likely to suffer
from repeated episodes of malaria and this raises
concerns over potential toxicity due to repeated short-
term exposure to the drugs.
Two longitudinal studies have therefore attempted to
address this question by assessing the efficacy, safety and
tolerability of amodiaquine-artesunate versus AL [55] and
amodiaquine plus sulphadoxine-pyrimethamine versus
artesunate-amodiaquine versus AL [56] after repeated use.
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Table 1 – Continued
Number given 
Study AL  compared  Participating 
number Design Comparator  Patients with total  countries  Key safety findings 
Abdulla  Randomized, Dispersible  Infants &  452 out  Kenya, There was no difference in the pattern of AEs 
et al 2008  investigator- formulation  children  of 899 Tanzania, Mali, seen in patients who received treatment with 
[11] blind of AL (5 to <35 kg) Benin, crushed AL tablets compared with those who 
Mozambique received the dispersible formulation. No new or 
unexpected AEs were identified and the most 
commonly reported AEs were also related to 
malaria.The most common drug-related AE was 
vomiting; this was more frequently reported in 
the lowest weight category.The number of SAEs 
was low (1–2% in both groups) and most of 
these were infections.There were no signs of 
ototoxicity.There were no clinically relevant 
findings or differences between study groups for 
ECG assessments, vital signs, or laboratory 
parameters.
*Study was not designed to compare artemether/lumefantrine with mefloquine/artesunate
†Artemether/lumefantrine over 60 hours
AE: adverse event;AL: artemether/lumefantrine; ECG: electrocardiogram; MAS: mefloquine/artesunate; SAE: serious adverse event; vs.: versusMalaria Journal 2009, 8(Suppl 1):S6 http://www.malariajournal.com/content/8/S1/S6
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Table 2 – Published studies with the six-dose AL regimen in Africa 
Design and patient  Comparators 
Authors Country population (no. of patients) Results
Bukirwa  Uganda Randomized, single- AL (n=204)  Overall, 261 (65%) of participants experienced AEs of moderate or severe 
et al 2006  blind, single centre in  ASAQ (n=204) intensity and there was no difference between the two treatment groups. SAEs 
[12] children (1–10 years) were uncommon with both regimens, with one occurring in each group and 
judged to be unrelated to study medication (ASAQ) or unlikely to be related to 
study medication (AL). No abnormalities in hearing or fine finger dexterity were 
detected.
Dorsey  Uganda Single-blind, AL (n=103 and All study regimens appeared to be safe and generally well tolerated. In the first 
et al 2007  randomized, single  202 treatments)  14 days, anorexia and weakness occurred more commonly in children treated with 
[13] centre in children  AQSP (n=111  AQSP than those receiving ASAQ or AL. A total of 45 SAEs were reported in 
(1–10 years) and 253  38 patients, but none of these were considered probably or definitely related to 
treatments) study  medication.
ASAQ (n=113 
and 232 
treatments)
Gürkov  Ethiopia Single centre in  AL (n=30)  The first randomized clinical trial to directly compare ototoxicity of AL with other 
et al 2008  adults and children  Quinine (n=35)  anti-malarial drugs. Pure tone audiometry and distortion product otoacoustic 
[14] >5 years of age Atovaquone/ emission levels revealed transient significant cochlear hearing loss in patients 
proguanil (n=32) treated with quinine but not in those treated with AL or atovaquone/proguanil.
Transitory evoked otoacoustic emission could be elicited in all examinations,
except for three patients in the quinine group on day 7, who suffered a transient 
hearing loss greater than 30 dB.There was no evidence of drug-induced brain 
stem lesions by brain stem evoked response audiometry.There was no 
detrimental effect of AL on peripheral hearing or brainstem auditory pathways;
however, transient hearing loss is common after quinine therapy due to temporary 
outer hair cell dysfunction.
Kamya  Uganda Single-blind, AL (n=210)  Both drugs were well tolerated and reported AEs were of mild or moderate 
et al 2007  randomized, single  DP (n=211) severity and consistent with symptoms of malaria.There were 6 SAEs reported in 
[15] centre in children  this study and all were judged unrelated to study medications.
(6 months to 10 years)
Mårtensson  Zanzibar Multicenter, AL (n=200)  Both drugs were well tolerated and most AEs were of mild severity. Similar 
et al 2005  randomized, open- ASAQ (n=208) proportions of moderate or severe AEs were reported by the two groups (10% 
[16] label in children  for AL vs. 12% for ASAQ).All severe AEs were associated with malaria and were 
(6–59 months) not attributed to the study drugs. No significant differences were seen in the 
mean counts of white blood cells and neutrophils during follow-up. Significant and 
similar increases in mean haemoglobin levels from baseline to day 42 were seen in 
both groups.
Mohamed  Sudan Two-centre, open- AL (n=72)  No AEs were recorded for patients given ASSP and 11 were recorded for patients 
et al 2006  label in children  ASSP (n=71) given AL (5 cases of gastric disturbance, 5 of excessive sleepiness and 1 of 
[17] and adults dizziness).All were mild and self-limited and no patients withdrew from the study 
because of an AE.
Yeka  Uganda Randomized , single  AL (n=199)  Most AEs were of mild or moderate severity and consistent with symptoms of 
et al 2008  centre, single-blinded  DP (n=215) malaria.The most commonly reported AEs in both groups were cough, coryza,
[18] study in children aged  abdominal pain, anorexia, weakness, diarrhoea and pruritus and there were no 
6 months to 10 years significant differences between groups.A total of 7 SAEs were reported (2.3% 
after DP and 1% after AL), but all were judged unrelated to study medication.
Mulenga  Zambia Randomized, open- AL (n=485)  AL and SP were generally well tolerated. SAEs were observed in 2 patients treated 
et al 2006  label, multicentre  SP (n=486) with SP and one patient treated with AL. Eleven patients (5 on AL and 6 on SP) 
[19] in adults had various symptoms possibly related to the study drugs but none were serious 
enough to interrupt the treatment.
Continued overleafMalaria Journal 2009, 8(Suppl 1):S6 http://www.malariajournal.com/content/8/S1/S6
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Table 2 – Continued
Design and patient  Comparators 
Authors Country population (no. of patients) Results
Adjei GO  Ghana Randomized, open  AL (n=111)  The majority of AEs were mild in intensity, overlapped with known malaria 
et al 2008  label in children  ASAQ (n=116) symptomology, and were mostly classified as unrelated to study medication.
[20] (6 months to 14 years) Drug-related AEs were rare. Possibly related AEs were pruritus (2 patients on 
ASAQ and 1 patient on AL) and fatigue/excessive sleepiness (5 patients on ASAQ 
and 4 patients on AL). Neurological examinations were conducted on 168 children 
(n=92 for ASAQ; n=76 for AL). Nystagmus was observed in two patients (1 per 
group), but both had a history of admission to a neonatal intensive care unit and 
either excessive emotional liability or cognitive impairment. One child in the AL 
group had a positive Romberg’s test (indicative of sensory ataxia) on day 3, but 
also had a history of cognitive impairment. No other neurological abnormalities 
were observed during the 28-day follow-up, at monthly visits or in patients who 
took multiple courses of treatment.Audiometry was assessed in 72 patients (n=37 
for ASAQ; n=35 for AL). Hearing thresholds were significantly elevated in treated 
patients compared with age- and sex-matched controls up to and including day 28,
but there were no differences after 9 to 12 months. (Note: full audiometry results 
are presented elsewhere).
Falade  Nigeria Randomized, open  AL (n=66)  Both drugs were well tolerated according to clinical and laboratory parameters.
et al 2008  label, single centre  ASAQ (n=66) The most common AEs were vomiting, anaemia, cough and abdominal pains and 
[21] in children (6 months  are frequent clinical findings among patients with malaria. No child was withdrawn 
to 10 years) because of an AE.
Faye  Senegal Randomized, open- ASAQ (n=360)  The side-effects of treatments were minor and consisted mainly of mild gastralgia,
et al 2007  label, multicentre in  AQSP (n=161)  dizziness, pruritus, asthenia, and vomiting.These disappeared at the end of 
[22] children and adults MAS (n=145)  treatment and did not require any specific treatment. No SAEs were observed and 
Six-dose AL  there were no severe alterations in renal or hepatic function for any of the drug 
(n=149) combinations.
Four-dose AL 
(n=140)
Koram  Ghana Two-centre, AL (n=51)  Some patients were withdrawn from the study due to AEs: 2 patients on day 1 due 
et al 2005  randomized, open- CQ (n=36)  to lethargy/inability to eat, (1 each for the CQ and SP groups), 3 patients due to 
[23] label in children  SP (n=27)  excessive vomiting/lethargy (all after ASAQ) and 1 patient due to excessive 
(6–59 months) ASAQ (n=54) vomiting and diarrhoea (this patient in the AL group had a concomitant 
hookworm infection).
Owusi-Agyei  Ghana Randomized, open  AL (n=223)  The incidence of AEs was comparable between the groups although a history of 
et al 2008  label in children aged  ASAQ (n=228)  body pain was more frequently reported in the ASAQ group compared with the 
[24] 6 months to 10 years ASCD (n=178) AL or ASCD groups (14.0% vs. 5.7% vs. 5.1%, respectively; p=0.01).
Sagara  Mali Randomized, single  AL (n=303)  AL and AS plus sulphamethoxypyrazine plus pyrimethamine were both well 
et al 2006  centre, open-label  AS plus sulpha- tolerated.The total number of reported AEs and the number of patients reporting 
[25] study in children  methoxypyrazine  any symptom/signs in the first week after treatment was similar in the groups.
(≥6months) and adults plus pyrimetha- Diarrhoea occurred more frequently after AL compared with AS plus 
mine (n=303) sulphamethoxypyrazine–pyrimethamine (3.6% vs. 1.0%, respectively; p=0.03). No 
SAEs occurred.
Sowunmi  Nigeria Randomized, open- AL (n=90)  AEs within the first week of treatment were reported by 21 children (9 after AL 
et al 2007  label, single centre, AQ plus sulpha- and 12 after AQ plus sulphalene plus pyrimethamine).There was no significant 
26] in children (≤10years) lene plus pyri- difference in the proportions of patients reporting AEs in both groups. Pruritus 
methamine  and weakness were significantly more frequent in the AQ plus sulphalene plus 
(n=91) pyrimethamine group, and vomiting was significantly more frequent in the AL 
group. No child was withdrawn because of drug intolerance.
Sutherland  Gambia Randomized, single  AL (n=406)  Minor complaints noted at the day 7 laboratory visit included headache (12% and 
et al 2005  centre, single-blind, CQSP (n=91) 11% in the CQSP and AL groups, respectively), anorexia (12% and 16%), diarrhoea 
[27] in children (1–10 years)  (7% and 4%), abdominal pain (5% and 5%), and pruritus (1% and 1%). No SAEs 
occurred in either group, and there were no deaths among children in the study.
Zongo  Burkina  Multicentre, AL (n=261)  Both drugs were well tolerated.AEs did not differ between groups apart from 
et al  Faso randomized, open- AQSP (n=260) pruritus, which was more common with AQSP than AL (16% vs. 3%, p<0·0001).
2007 [28] label in children  Only 2 SAEs (both haemoglobin levels below 50 g/L) were reported; 1 SAE was 
(6 months to 10 years) due to early treatment failure after AQSP and 1 SAE was due to late clinical failure 
after AL.
Continued overleafThese studies in Ghanaian and Ugandan children
indicated all treatments were efficacious, but the various
treatments were associated with slightly different adverse
event profiles. For example, treatment with amodiaquine
plus sulphadoxine-pyrimethamine had a greater risk com-
pared with AL of anorexia, weakness and subjective fever
and a greater risk compared with artesunate-amodiaquine
of weakness and subjective fever. Children treated with
AL, however, had a higher risk of elevated temperature
than those receiving artesunate-amodiaquine [56]. In
both studies, repeated administration of AL did not seem
to be associated with an increased risk of adverse drug
reactions. The study in Ghanaian children also included
neurological examinations for children treated with
repeated artemisinin-based regimens. This did not
identify any abnormal neurological signs that were
considered related to artemisinin [55].
Comparison with other anti-malarial therapies
The safety of the six-dose regimen of AL has been
compared with MAS in two Novartis-sponsored, open-
label randomized trials [7,8,52], as summarized in
Table 1. In these two studies, 314 patients received AL and
105 patients received MAS. Overall, AL was at least as well
tolerated as MAS, and had a similar safety profile
(Table 6) [52]. Only one patient, who developed urti-
carial rash, experienced a serious adverse event that was
thought to be treatment-related [52]. Independent studies
have also compared AL with other anti-malarial therapies
as shown in Table 2, Table 3 and Table 4 [12–40]. These
studies showed that AL was at least as well tolerated as the
various comparators (AQSP, ASAQ, ASCD, ASSP, AS plus
sulphamethoxypyrazine plus pyrimethamine, atovaquone/
proguanil, CQ, CQSP, DP, DNP, MAS, quinine, or SP)
used in clinical trials.
Safety in pregnancy
Pregnant women with symptomatic malaria, and
especially those in their second and third trimesters, are
more likely to develop severe malaria than other women
[2]. In addition, this is often complicated by pulmonary
oedema and hypoglycaemia [2]. Prompt, safe, and
effective treatment is, therefore, recommended in this
high risk group to reduce maternal mortality, foetal death
and premature labour [2]. ACT can be used in uncom-
plicated malaria in the second and third trimester. The use
of ACT in the first trimester should, however, only be
considered if they are the only effective treatment
available and the benefits outweigh the risks of treatment
[2,4]. In severe malaria, ACT is preferred over quinine due
to the hypoglycaemia associated with quinine. Until
recently there has been limited evidence available to
support the use of ACT in early pregnancy; however,
McGready  et al published data on the use of AL in
pregnancy in 2009 [57]. These data were from a pros-
pective eight-year study in Thailand on pregnant women
Malaria Journal 2009, 8(Suppl 1):S6 http://www.malariajournal.com/content/8/S1/S6
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Table 2 – Continued
Design and patient  Comparators 
Authors Country population (no. of patients) Results
Zongo  Burkina  Multicentre, AL (n=188)  All drugs were well tolerated. However, abdominal pain was reported more often 
et al 2007  Faso randomized, open- AQSP (n=184)  in the AQSP and AL groups than in the DP group (24% and 20% vs. 9%,
[29] label in children  DP (n=187) respectively), headache was more common in the AL group than in the AQSP and 
(≥6 months) DP groups (21% vs. 14% and 10% respectively) and pruritus was more common in 
the AQSP group than in the AL and DP groups (18% vs. 6% and 3%, respectively).
No SAEs were reported in this study.
Fanello  Rwanda Randomized, open- AL (n=251)  AEs concomitant with the administration of the study drug were reported by 
et al 2007  label, 2-centre in  AQSP (n=249) 251 patients (52.21% after AQSP and 48.21% after AL).AEs that were possibly or 
[30] children  probably related to the study drug were reported by 22.73% of patients after 
(12–59 months) AQSP and 14.47% after AL (p=0.06).The most frequently reported AEs after 
AQSP were fatigue, anorexia, vomiting and abdominal pain and the AEs most 
frequently reported after AL were cough and diarrhoea.
Ndayiragije  Burundi Multicentre, AL (n=142)  AEs were similar in the two groups, although vomiting on days 1 and 2 was more 
et al 2004  randomized, open- ASAQ (n=153) frequent in the ASAQ group (13.1% and 5.3%, respectively) than in the LA group 
[31] label in children  (5% and 0.7%, respectively).
(<5 years)
Van den  Republic  Randomized, single  AL (n=106)  The most frequent AEs reported during the 3 days of treatment were vomiting,
Broek et al  of Congo centre, open-label  ASAQ (n=101)  diarrhoea, abdominal pain and anorexia.The frequency of these AEs was low 
2006 [32] study in children  ASSP (n=91) (around 10% of children) and did not differ among the groups.There were two 
(6–59 months) cases of urticaria (1 after ASAQ and 1 after ASSP), but these developed after 
completion of the treatment. No SAEs were reported.
AL:Artemether/lumefantrine; CQ: Chloroquine; SP: Sulphadoxine/pyrimethamine; CQSP: Chloroquine/sulphadoxine/pyrimethamine;AS:Artesunate;AQ:
Amodiaquine;ASAQ:Amodiaquine/artesunate;AQSP:Amodiaquine/sulphadoxine/pyrimethamine; DP: dihydroartemisinin/piperaquine; MAS:
mefloquine/artesunateMalaria Journal 2009, 8(Suppl 1):S6 http://www.malariajournal.com/content/8/S1/S6
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Table 3 – Published studies with the six-dose AL regimen in Asia
Design and patient  Comparators 
Authors Country population (no. of patients) Results
South-East Asia
Krudsood   Thailand Randomized, open- AL (n=41)  No deterioration in clinical or biochemical responses occurred after treatment 
et al 2003   label, single centre in  DNP (n=89) with AL or DNP. Minor symptoms (nausea, headache, and dizziness) were seen in 
[33] adults both groups.These could not be differentiated from malaria signs and symptoms 
as they resolved simultaneously with fever 1-4 days after treatment.There were 
no SAEs or deaths, and no neurological or neuropsychiatric manifestations were 
seen during treatment or during the 28-day follow-up period.
Stohrer   Laos Randomized, open- AL (n=53)  Most of the recorded treatment emergent symptoms/signs (TESS) on day 0 and 
et al 2004   label, hospital and  MAS (n=55) day 3 were mild or moderate in severity, and were symptoms typical of malaria.
[34] community-based  There were no significant differences between treatment groups in the incidence 
study in adults and  of gastrointestinal disorders like abdominal pain, nausea, vomiting, diarrhoea or 
children (≥10 kg) anorexia (12.8% for AL vs. 12.0% for MAS), or nervous system disorders like 
headache, dizziness, weakness, or sleep disorder (29.8% for AL vs. 41.5% for MAS).
Apart from severe diarrhoea (1 patient in the AL group) and sleep disorder and 
dizziness (1 patient in the MAS group), no other potentially drug-related AEs were 
reported.
Mayxay   Laos Randomized, open- AL (n=110)  The proportion of patients with symptoms and signs before treatment, which may 
et al 2004   label, single centre, MAS (n=110)  subsequently be confused with drug-related AEs, did not differ significantly 
[35] in adolescents and  CQSP (n=110) between the 3 groups.The proportion of patients with ≥1 potential side-effect 
adults (12–19 years) was higher in the MAS group (52%) than in the CQSP group (44%) or the AL 
group (27%).Three patients in the MAS group had serious neuropsychiatric effects 
following treatment, 1 patient developed fever and a Glasgow coma score of 8/15 
due to the presence of gametocytes on day 15 after CQSP and 1 patient had 
hallucinations and uncharacteristic anxiety on day 20.
Ratcliff   Indonesia Randomized, open- AL (n=387)  AEs were assessed in patients without the symptom at enrolment and were 
et al 2007   label, 2-centre in  DP (n=387)  similar between groups apart from a two-fold increased risk of diarrhoea on days 
[36] children (body weight  1 and 2 in more patients receiving DP compared with AL (95% CI 1·3–3·3;
≥10 kg) and adults  p=0.003). By day 7, the risk of diarrhoea was 5% in both treatment groups.
Although 35% of patients developed a headache on days 1 and 2 after DP 
compared with 23% of patients given AL, the difference was not significant as 
headache was a common symptom at presentation.
Hutagalung   Thailand Randomized, open- AL (n=245)  AL and MAS were well tolerated.Vomiting of one or more doses of drug occurred 
2005 [37] label, 2-centre, in  MAS (n=245) in 2.1% in the AL group and 0.8% of the MAS group (relative risk, 2.5; 95% CI,
children (>10 kg)  0.5-12.7; p=0.45).The rates of early vomiting (within one hour) of dosing were 
and adults very low (around 2%) and did not differ between groups.The most commonly 
reported and possibly drug-related AEs were effects on the gastrointestinal 
(abdominal pain, anorexia, nausea, diarrhoea and vomiting more than 1 hour after 
dosing) and central nervous system (headache, dizziness).There were fewer AEs in 
the AL group compared with the MAS group, although this was not statistically 
significant. No SAEs were reported.
South Asia
van den   Bangladesh Randomized, open- AL (n=121)  All treatments were well tolerated. Mild AEs reported during the 3 days of 
Broek et al   label, single centre, MAS (n=121)  treatment were headache, vomiting, nausea and dizziness.The frequency of these 
2005 [38] in adults and children  CQSP (n=122) AEs was generally higher after MAS compared with AL (p<0.05).After CQSP 
(≥1 year) treatment, complaints were of intermediate frequency, but vomiting occurred 
more in this group. Other AEs were anorexia, skin itching and deafness with CQSP,
sleeplessness, anorexia, skin itching/rash, epigastric pain and excessive sweating 
with MAS and blurred vision and anorexia with AL. No severe AEs were observed.
Thapa   Nepal Randomized, open- AL (n=66)  The most commonly reported symptoms at presentation apart from fever were 
et al 2007  label, single centre, in  SP (n=33) headache (97% in the AL group and 88% in the SP groups), nausea (42% and 64%,
[39] adults and children  respectively), and vomiting (39% and 46%, respectively). Other gastrointestinal,
(>5 years) neurological, musculoskeletal, respiratory, and dermatologic complaints were much 
less frequent. During treatment, <12.5% of patients reported one or more 
symptoms, with the majority of mild intensity, and no significant differences seen 
between groups.There were no group-specific differences in changes in pulse or 
blood pressure during initial therapy. ECGs were conducted in 10 patients in the 
AL group and 8 patients in the SP group and no changes in QTc were observed 
during treatment with either drug.
AL: artemether/lumefantrine; ECG: electrocardiogram; SP: sulphadoxine/pyrimethamine; CI: confidence interval; CQSP: Chloroquine/sulphadoxine/
pyrimethamine; DP: Dihydroartemisinin/piperaquine; DNP: dihydroartemisinin/napthoquine/trimethoprim; MAS: mefloquine/artesunate; vs.: versusexposed to artemisinin antimalarials. In this study, birth
outcomes did not differ significantly from community
rates of congenital malformations and stillbirth [57]. In
addition, data from a prospective observational study to
compare the safety of AL and SP in pregnant women
treated for symptomatic falciparum malaria was
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Table 4 – Pooled analyses of data on the six-dose AL regimen
Authors  Number of studies, regions, types of patient and drugs (number of patients) Results
Mueller et al  11 randomized clinical trials  Almost every patient reported at least one AE during treatment.The rate and type of AEs were 
2006 [40] conducted in Thailand, India, Europe, generally comparable between the 6- and four-dose groups. Most AEs were reported during the 
China, Bangladesh in adolescents  first 3 days of treatment and were of mild or moderate severity. Severe AEs were infrequent 
and adults aged >12 years  (5.9% for the six-dose group, 3.8% for the four-dose group).The most common AEs reported 
for AL included headache, asthenia, dizziness, myalgia, arthralgia, nausea, anorexia and fatigue; all 
Six-dose AL (n=598)  of these could have been disease-related. Only a small proportion of patients reported AEs that 
Four-dose AL (n=770)  were suspected to be drug-related and these occurred less frequently with the six-dose AL 
group than in the four-dose group. Drug-related AEs were more frequent for most comparator 
Comparators included: treatments than six-dose AL regimen, and for MAS, these were higher than the rates seen in 
Mefloquine (n=126)  both the six-dose and four-dose groups.
Quinine/SP (n=114) 
Chloroquine (n=90)  SAEs were reported by 0.6% of patients in the six-dose group and 0.8% of patients in the 
MAS (n=335)  four-dose group. No SAEs in patients in the six-dose group (dyspnoea, febrile coma, pulmonary 
Halofantrine (n=52) oedema, typhoid fever) were considered to be drug-related. SAEs in the four-dose group 
included (one each of) abnormal laboratory values, anaemia, falciparum malaria, malaria relapse,
severe malaria, and two cases of hepatitis; only the reports of anaemia and malaria relapse were 
suspected to be drug-related. For the comparators, one SAE was reported in each of the MAS 
and chloroquine groups.
There was no difference in neurotoxicity between any of the groups, apart from paresthesia,
which was only present in the four-dose AL group and the MAS group. Headache and dizziness 
were the most frequently reported neurological AEs. Decreased hearing (hypoacusis) was 
reported by 1.6% of patients in the four-dose group; there were no reports in the six-dose 
group.All cases of hypoacusis were mild, apart from one case of moderate severity and only two 
were considered to be drug-related. For the comparators, only patients in the MAS group 
reported hypoacusis (6.3%).
Makanga et al  8 clinical trials in Gambia,Tanzania, The majority of patients reported at least one AE after dosing; these were generally mild or 
2006 [41] Kenya, Nigeria and Thailand in  moderate in severity. Severe AEs were infrequent (5.2% for the six-dose and 7.0% for the 
children (5–25 kg)  four-dose AL groups).The most commonly reported AEs included cough, anaemia, anorexia,
vomiting, hepato-/splenomegaly, headache, and diarrhoea, with most of these possibly related to 
Six-dose AL (n=343)  malaria.The proportion of patients with AEs was similar between the 5 to <10, 10 to <15, and
Four-dose AL (n=201) 15–25 kg body weight groups for both dosing groups.There were some differences between 
body weight groups for certain AEs such as headache and dizziness.These subjective AEs 
appeared less commonly in very small infants, but this may have been related to the patients’ 
limited ability to verbalize symptoms and as such is not considered clinically relevant.
Drug-related AEs were only reported for a small number of patients and occurred more 
frequently in the six-dose group.
Only three patients (0.9%) in the six-dose group reported SAEs (convulsion, urticaria, viral 
hepatitis) compared with one patient (0.5%) in the four-dose group (pneumonia). Of these SAEs,
only the case of severe urticaria, which required hospitalisation, was considered drug-related. In 
addition to these SAEs, one patient died, but this was from causes unrelated to study treatment.
Fewer patients in the six-dose than in the four-dose group reported AEs that were related to 
the central nervous system; headache (9.9% vs. 40.3%, respectively) and dizziness (3.8% vs.
16.4%, respectively) were the most commonly reported events. Other neurological AEs reported 
in the six-dose and four-dose groups included clonus (3.8% vs. 1.0%, respectively), hyperreflexia 
(1.7% vs. 0.5%, respectively), and convulsions (0.3% vs. 1.0%). Patients in the six-dose group failed 
to report the following AEs which were seen in the four-dose group: nystagmus, ataxia, and 
coordination abnormal (all 1.0–1.5%) and decreased hearing (1.5%).The cases of decreased 
hearing were not considered to be drug-related.
For cardiac safety assessments, the incidence of QTc changes within specific ranges was 
comparable between groups, and it is unlikely that there is an increased cardiac risk in the 
paediatric patients included in this analysis. Clinical laboratory parameters showed no major 
differences between the groups; findings were consistent with acute malaria.
AE: adverse event;AL: artemether-lumefantrine; MAS: mefloquine plus artesunate; SAE: serious adverse event; SP: sulphadoxine plus pyrimethamine vs.:
versuspresented at ASTMH Annual Meeting in December 2008
[58]. This study analysed data from 1,001 pregnant women
(AL: n=495; SP: n=506) and their foetuses/newborns (AL:
n=470; SP: n=477). There were no clinically relevant
differences in perinatal mortality, neonatal mortality, still
births, preterm deliveries, gestational age-adjusted low
birth weight or birth defects between the two groups.
Post-marketing experience
As of July 2009, 250 million AL treatments (70% of which
were for children) have been delivered to malaria-
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Table 5 – In vitro IC50 for hERG tail current in HEK 293 cells and cardiac
safety index of antimalaria drugs [52]
IC50 / therapeutic 
free plasma 
Agent IC50 – IKr (μM) concentration*
Halofantrine 0.04 0.07
Chloroquine 2.5 6.3
Mefloquine 2.6 50
Desbutyl-lumefantrine 5.5 ~2,900
Lumefantrine 8.1 48
* Cardiac safety index.Values greater than 30 suggest cardiotoxicity is
unlikely
hERG: human ether-a-go-go related gene; IC50: inhibitory concentration
50 (the concentration that gives 50% inhibition)
Figure 1
Placebo-corrected mean change in QTc (Fridericia’s formula) from time-averaged baseline in healthy volunteers. [Data on file
(study A2101), Novartis].AL=artemether/lumefantrine; CI=confidence interval.
Table 6 – Most frequently reported adverse events that occurred at a
frequency of >10% in either group of patients enrolled in comparator
studies [7,8,52]
Adverse event 
preferred term AL n(%) n=314 MAS n(%) n=105
Pyrexia 183 (58.3) 63 (60.0)
Headache 166 (52.9) 46 (43.8)
Dizziness 123 (39.2) 37 (35.2)
Anorexia 108 (34.4) 37 (35.2)
Asthenia 108 (34.4) 33 (31.4)
Arthralgia 99 (31.5) 31 (29.5)
Nausea 82 (26.1) 34 (32.4)
Myalgia 74 (23.6) 19 (18.1)
Sleep disorder 70 (22.3) 30 (28.6)
Chills 67 (21.3) 20 (19.0)
Vomiting 50 (15.9) 22 (21.0)
Abdominal pain 61 (19.4) 20 (19.0)
Palpitation 55 (17.5) 17 (16.2)
Hepatomegaly 48 (15.3) 8 (7.6)
Splenomegaly 40 (12.7) 12 (11.4)
Fatigue 34 (10.8) 8 (7.6)
AL: artemether/lumefantrine; MAS: mefloquine/artesunateendemic countries. Post-marketing experience has not
identified any new specific safety concerns apart from
hypersensitivity and skin reactions (allergies), a recog-
nized class effect for artemisinin derivatives [2].
Conclusions
This review summarizes some of the safety and tolera-
bility data on AL (Coartem®) from published Novartis-
sponsored and independently-sponsored clinical trials.
Data are available to support the use of a six-dose regimen
of AL as a safe and well-tolerated treatment for P.
falciparum malaria or malaria due to mixed infection
including  P. falciparum in adults, adolescents, children
and infants. Indeed, the safety profile of this drug is
similar in both adults and children, and many of the
reported adverse events are typical of symptoms of
malaria or concomitant infections that are commonly
seen in these patient populations. Reported adverse
events are mainly of mild or moderate severity, with very
few serious adverse events reported and even fewer
serious adverse events considered related to treatment. In
addition, no notable neurological adverse events or
cardiac safety concerns were identified in the many
studies that examined the safety of AL. As patients (and
especially children) often take repeated courses of
treatment for malaria, it is reassuring to note that data are
available that show repeated administration of AL is not
associated with an increased risk of adverse drug reactions,
in particular with regard to neurological adverse events. In
addition, a thorough review of the clinical data for AL
does not identify any potential cardiac safety issues. Data
are also available to show that there were no clinically
relevant differences in perinatal mortality, neonatal
mortality, still birth, pre-term delivery, low birth weight
and spontaneous abortion in women exposed to AL
compared with SP during pregnancy.
In conclusion, AL is a safe and well-tolerated treatment
for P. falciparum infections that should help fight malaria.
Indeed, as of July 2009, 250 million AL (Coartem®) treat-
ments have been delivered and post-marketing experience
confirms the favourable safety and tolerability profile for
this drug. In addition, this wealth of safety evidence has
not identified any safety concerns for AL apart from rare
type 1 hypersensitivity reactions, a recognized class effect
of artemisinin derivatives [2].
List of abbreviations
ACT: Artemisinin-based combination therapy; AE: Adverse
event; AL: Artemether/lumefantrine; AQ: Amodiaquine;
AQSP: Amodiaquine plus sulphadoxine-pyrimethamine;
AS: Artesunate: ASAQ: Artesunate plus amodiaquine ;
ASTMH: American Society of Tropical Medicine and
Hygiene; CQ: Chloroquine;CQSP: Chloroquine plus
sulphadoxine-pyrimethamine; DNP: Dihydroartemisinin
plus napthoquine plus trimethoprim ; DP: Dihydro-
artemisinin-piperaquine; ECG: Electrocardiogram (also
known as EKG); hERG: Human ether-a-go-go related
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Figure 2
Relationship between QTc (Fridericia’s formula) and maximum plasma concentration (Cmax) in healthy volunteers. [Data on
file (study A2101), Novartis]. Note: the threshold of relevance for QTc change is 10 msec vs. placebogene; IC50: Inhibitory concentration 50 (the concentra-
tion that gives 50% inhibition); ICH: International
Conference on Harmonization; IKr: Rectifying K+ current;
MAS: Mefloquine plus artesunate ; MedDRA: Medical
Dictionary for Regulatory Activities; SAE: Serious adverse
event; SP: Sulphadoxine-pyrimethamine; vs.: Versus;
WHO: World Health Organization.
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